NO RESISTANCE TO TENOFOVIR ALAFENAMIDE ( TAF) IN ADULT, HBEAG- POSITIVE AND HBEAG- NEGATIVE PARTICIPANTS WITH CHRONIC HEPATITIS B INFECTION TREATED WITH TAF FOR UP TO 8 YEARS.

被引：0
|
作者：
Mateo, Roberto [1 ]
Chan, Henry Lik Yuen [2 ]
Marcellin, Patrick [3 ]
Pan, Calvin Pan [4 ]
Yazdi, Tahmineh [1 ]
Chang, Silvia [1 ]
Han, Dong [1 ]
May, Lindsey [1 ]
Marceau, Caleb [1 ]
Richards, Christopher [1 ]
Manhas, Savrina [1 ]
Ho, Pui Yan [1 ]
Li, Robert [1 ]
Xu, Simin [1 ]
Martinez, Clarissa [1 ]
Liu, Yang [1 ]
Peinovich, Nadine [1 ]
Lopez, Andrew [1 ]
Abramov, Frida [1 ]
Flaherty, John F. [1 ]
Mo, Hongmei [1 ]
Izumi, Namiki [5 ]
Buti, Maria [6 ,7 ]
Dr Shalimar [8 ]
Lim, Young-Suk [9 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[3] Beaujon Hosp, Clichy, France
[4] NYU, Grossman Sch Med, New York, NY USA
[5] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan
[6] Hosp Univ Vall Dhebron, Barcelona, Spain
[7] Inst Carlos III, Ciberehd, Barcelona, Spain
[8] All India Inst Med Sci, New Delhi, India
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1430-C
引用
收藏
页码：S532 / S533
页数：2
相关论文
共 50 条
  • [31] CHARACTERISTICS OF GUT MICROBIOTA ASSOCIATED WITH FUNCTIONAL CURE IN CHRONIC HEPATITIS B PATIENTS WITH HBEAG- NEGATIVE; POSSIBLE INHIBITION OF HEPATITIS B VIRUS BY BUTYRATE- PRODUCING BACTERIA
    Honda, Takashi
    Murayama, Asako
    Inukai, Yosuke
    Muto, Hisanori
    Yokoyama, Shinya
    Yamamoto, Kenta
    Ito, Takanori
    Imai, Norihiro
    Ishizu, Yoji
    Ishigami, Masatoshi
    Yoshio, Sachiyo
    Ishikawa, Tetsuya
    Kawashima, Hiroki
    Kato, Takanobu
    HEPATOLOGY, 2023, 78 : S594 - S594
  • [32] FOUR YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB), PRELIMINARY ANALYSIS
    Gane, Edward J.
    Lee, Samuel S.
    Heathcote, E. Jenny
    Sievert, William
    Trinh, Huy N.
    Kaita, Kelly D.
    Younossi, Zobair M.
    George, Jacob
    Marcellin, Patrick
    Coombs, Derek H.
    Anderson, Jane
    Mondou, Elsa
    HEPATOLOGY, 2010, 52 (04) : 559A - 559A
  • [33] Changes of serum HBsAg levels in HBeAg-negative chronic hepatitis B patients treated with tenofovir
    Papatheodoridis, George V.
    Triantos, Christos K.
    Hadziyannis, Emilia
    Zisimopoulos, Konstantinos
    Georgiou, Anastasia
    Margariti, Katerina
    Deutsch, Melanie
    Nikolopoulou, Vasiliki
    Manolakopoulos, Spilios
    HEPATOLOGY, 2013, 58 : 686A - 687A
  • [34] PEGINTERFERON ALFA2b PLUS TDF TREATMENT IN ADULTS WITH HBEAG- POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: A PILOT, OPEN- LABEL, PROSPECTIVE COHORT STUDY
    Liu, Min
    Zuo, Lili
    Zhang, Yuting
    Xiao, An
    Wang, Yilan
    Bu, Bing
    Chen, Jiayi
    Zhu, Ling
    Yue, Wei
    Geng, Jiawei
    Xia, Xueshan
    HEPATOLOGY, 2023, 78 : S537 - S538
  • [35] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
    Thompson, A.
    Gane, E.
    Fung, S.
    Seto, W. K.
    Flaherty, J. F.
    Suri, V.
    Lin, L.
    Gaggar, A.
    Subramanian, G. M.
    Chuang, W. L.
    Agarwal, K.
    Janssen, H. L.
    Buti, M.
    Chan, H. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 109 - 109
  • [36] Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B
    Chan, H. L.
    Fung, S.
    Seto, W. K.
    Gane, E.
    Flaherty, J. F.
    Suri, V.
    Lin, L.
    Gaggar, A.
    Subramanian, G. M.
    Chuang, W. L.
    Agarwal, K.
    Janssen, H. L.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S25
  • [37] Resistance surveillance in HBeAg-chronic hepatitis B patients (CHB) patients treated with adefovir dipivoxil (ADV) for two years.
    Gibbs, CS
    Xiong, S
    Yang, H
    Westland, CE
    Delaney, WE
    Colledge, D
    Bartholomeusz, A
    Thibault, V
    Benhamou, Y
    Angus, P
    Wulfsohn, M
    Fry, J
    Brosgart, CL
    Locarnini, S
    ANTIVIRAL RESEARCH, 2003, 57 (03) : A43 - A43
  • [38] Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg-Negative Chronic Hepatitis B
    Tseng, Cheng-Hao
    Lee, Teng-Yu
    Chen, Chi-Yi
    Huang, Chung-Feng
    Chen, Po-Yueh
    Jang, Tyng-Yuan
    Yang, Tzeng-Huey
    Wu, Chia-Ching
    Hsu, Yao-Chun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025,
  • [39] THREE YEARS OF TENOFOVIR DISOPROXIL (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS
    Heathcote, E. Jenny
    Gane, Edward J.
    De Man, Robert A.
    Lee, Samuel S.
    Flisiak, Robert
    Manns, Michael P.
    Tchernev, Konstantin G.
    Kurdas, Ayse Oya Oevuenc
    Shiffman, Mitchell L.
    Marcellin, Patrick
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    HEPATOLOGY, 2009, 50 (04) : 533A - 534A
  • [40] Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora (vol 14, 1232180, 2023)
    Long, Jianfei
    Gong, Jingru
    Zhu, Han
    Liu, Xiaolin
    Li, Ling
    Chen, Bicui
    Ren, Hongyan
    Liu, Chao
    Lu, Huiping
    Zhang, Jiming
    Wang, Bin
    FRONTIERS IN MICROBIOLOGY, 2023, 14
12345